Literature DB >> 21382685

Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry.

Thomas Kim1, Amy London, Evan D Kharasch.   

Abstract

A fast, sensitive and selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of alfentanil and midazolam in human plasma has been developed and validated. Alfentanil and midazolam were extracted from plasma using a mixed-mode cation exchange solid phase extraction method, with recoveries of both compounds greater than 80% at 3 different concentrations (1, 10 and 100ng/ml). Compounds were analyzed on a C(18) column with a water and methanol mobile phase gradient with acetic acid as an additive, at a flow rate of 0.3ml/min. The working assay range was linear from 0.25 to 100ng/ml for each compound. The signal to noise ratio was 80 and 40 for alfentanil and midazolam, respectively, at the lowest concentration calibration standard, with less than 10% matrix suppression by human plasma at this concentration. Alfentanil and midazolam were stable in human plasma during storage at -80°C, processing, and analysis. The procedure was validated and applied to the analysis of plasma samples from healthy human subjects administered oral and intravenous alfentanil and midazolam.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21382685      PMCID: PMC3089954          DOI: 10.1016/j.jpba.2011.01.040

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  26 in total

1.  Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus.

Authors:  G T Tucker; J B Houston; S M Huang
Journal:  Clin Pharmacol Ther       Date:  2001-08       Impact factor: 6.875

2.  Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers.

Authors:  J W Mandema; B Tuk; A L van Steveninck; D D Breimer; A F Cohen; M Danhof
Journal:  Clin Pharmacol Ther       Date:  1992-06       Impact factor: 6.875

3.  The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.

Authors:  E D Kharasch; M Russell; D Mautz; K E Thummel; K L Kunze; A Bowdle; K Cox
Journal:  Anesthesiology       Date:  1997-07       Impact factor: 7.892

4.  Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.

Authors:  E D Kharasch; C Jubert; T Senn; T A Bowdle; K E Thummel
Journal:  J Clin Pharmacol       Date:  1999-07       Impact factor: 3.126

5.  Determination of fentanyl and alfentanil in plasma by high-performance liquid chromatography with ultraviolet detection.

Authors:  K Kumar; D J Morgan; D P Crankshaw
Journal:  J Chromatogr       Date:  1987-08-07

6.  Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.

Authors:  Evan D Kharasch; Alysa Walker; Christine Hoffer; Pamela Sheffels
Journal:  Clin Pharmacol Ther       Date:  2004-11       Impact factor: 6.875

7.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

Authors:  T Shimada; H Yamazaki; M Mimura; Y Inui; F P Guengerich
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

8.  Alfentanil pharmacokinetics and metabolism in humans.

Authors:  W Meuldermans; A Van Peer; J Hendrickx; R Woestenborghs; W Lauwers; J Heykants; G Vanden Bussche; H Van Craeyvelt; P Van der Aa
Journal:  Anesthesiology       Date:  1988-10       Impact factor: 7.892

9.  Determination of alfentanil and noralfentanil in human plasma by gas chromatography-mass spectrometry.

Authors:  D S Mautz; R Labroo; E D Kharasch
Journal:  J Chromatogr B Biomed Appl       Date:  1994-08-05

10.  The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient.

Authors:  M Chauvin; F Bonnet; C Montembault; J C Levron; P Viars
Journal:  Anesth Analg       Date:  1986-10       Impact factor: 5.108

View more
  2 in total

1.  Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.

Authors:  E D Kharasch; A Francis; A London; K Frey; T Kim; J Blood
Journal:  Clin Pharmacol Ther       Date:  2011-05-11       Impact factor: 6.875

2.  Development and validation of a sensitive assay for analysis of midazolam, free and conjugated 1-hydroxymidazolam and 4-hydroxymidazolam in pediatric plasma: Application to Pediatric Pharmacokinetic Study.

Authors:  Ganesh S Moorthy; Harini Jogiraju; Christina Vedar; Athena F Zuppa
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-09-28       Impact factor: 3.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.